|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Insomnia - Future of Innovative Orexin Drug Class in Doubt
Datamonitor, July 2010, Pages: 257
The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.
Scope
- Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.
- In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.
- Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.
Highlights of this title
In 2019, the value of the seven major insomnia market is forecast to reach $3.5 billion. While growth of the US market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.
Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.
Three orexin receptor antagonists are currently under late stage clinical development by two Big Pharma players; GlaxoSmithKline and Merck. While safety observations raised in a Phase III trial of almorexant are of concern to developers, it has potential to become the most successful pipeline candidate.
Key reasons to purchase this title
- Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.
- Identify potential licensing opportunities based on product portfolios and anticipated market needs.
- Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.
Customers who bought this item also bought
Undiagnosed Sleep Disorder Market Offers Growth Opportunities
The Global Market For Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in A High-Value CNS Therapy Area
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
Insomnia Market Forecast
|
|
|
|
